Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus docetaxel vs placebo plus docetaxel in metastatic castration-resistant prostate cancer
CTR20201264Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bristol Myers Squibb. Started Aug 2020; status: terminated.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20201264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201264.